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Inactivated polio vaccine launch in Nepal: a public health 
milestone
On Sept 18, 2014, as part of the Global Polio Eradication 
Initiative (GPEI), Nepal became the ﬁ rst GAVI-
supported country in the world to introduce one dose 
of inactivated poliomyelitis vaccine (IPV) into routine 
immunisation schedules at 14 weeks. The launch at 
Tribhuvan University Teaching Hospital, Kathmandu, is a 
signiﬁ cant step, but there are challenges ahead.
Introduced in 1955, IPV was the ﬁ rst vaccine against 
polio—its discovery was a great advance in public 
health.1  Yet, it was eventually the oral polio vaccine 
(OPV) that became the world’s preferred vaccine because 
of lower cost, ease and safety of production, a simple 
route of oral delivery, and its eﬃ  cacy in stopping virus 
circulation.2,3  OPV was included in routine immunisation 
programmes, and the GPEI still uses OPV extensively 
in supplementary immunisation activities in eﬀ orts to 
eradicate polio. Since 1988, the global incidence of polio 
has fallen by more than 99%.4
However, in rare cases, OPV can cause vaccine-
associated paralytic poliomyelitis (2–4 cases per million 
birth cohort per year) and circulation of vaccine-derived 
poliovirus.5 OPV contains certain live attenuated strains 
of the virus that can sometimes mutate and revert 
to virulent vaccine-derived poliovirus (mostly type 
2 poliovirus), as opposed to IPV which contains fully 
inactivated or killed strains. As long as live attenuated 
strains are used in polio vaccines, ﬁ nal eradication 
cannot occur. IPV therefore mitigates risks posed by 
OPV. New evidence from India also suggests that when 
IPV is given to OPV-vaccinated individuals, better 
immunity is achieved.6
It is no coincidence that Nepal is the ﬁ rst of 72 planned 
GAVI-funded countries to introduce IPV. After stopping 
polio transmission in 2000 and responding eﬀ ectively to 
subsequent importations from India, the last case was in 
2010.7,8 Nepal also has a high-performing immunisation 
programme, with coverage rising from 43% in 1990 
to 90% in 2012.9 The immunisation programme 
has strong political commitment, and eﬀ ective 
partnerships between government, civil society, and 
international organisations including WHO, UNICEF, 
Rotary International, GAVI, and USAID. Professional 
associations have had a pivotal role: the Nepal Paediatric 
Society and the Society of Public Health Physicians 
Nepal were advocates for the intro duction of IPV. But 
there are challenges ahead with IPV introduction, 
and carefully crafted and ﬁ eld-tested communication 
eﬀ orts are needed to explain the issues to the public and 
professionals alike.
First, the introduction of the new vaccine is to be used 
alongside an existing vaccine for the same disease. One 
dose of IPV is to be introduced in parallel with OPV to 
particularly bolster immunity to type 2 poliovirus (type 
2 causes most of the current vaccine-related problems). 
Subsequently there will be a switch in the kind of 
OPV from that containing type 1, 2, and 3 poliovirus 
(trivalent OPV) to one without type 2 (bivalent OPV). 
Once virus circulation has been stopped everywhere, 
OPV can be withdrawn. The science is complex and 
a challenge to explain to the medical profession and 
caregivers. In Nepal, media outlets gave an early sense 
of how the lay public could respond to IPV. One noted 
that IPV was “the latest antidote to polio” and reported 
an expert as saying that it “[boosted] immune system 
big time”.10 Another source ran with the headline: “Polio 
vaccination to be intravenous”,11 perhaps confusing the 
inactivated strains in IPV given intramuscularly.
Second, in most countries, new vaccines mean either 
more injections in a given immunisation session, or 
more sessions. Multiple injections at the same time 
pose logistical and communication challenges, and have 
opportunity costs. Health professionals might worry 
about parental concerns and caregivers might in some 
circumstances object to more injections for a distressed 
child.12 Alternatively, increasing the number of visits 
could lead to increased dropout rates. IPV is best given 
at 14 weeks. But to avoid three injections at 14 weeks 
(IPV, pneumococcal conjugate vaccine, and pentavalent 
vaccine [diphtheria, tetanus, pertussis, hepatitis B, 
and Haemophilus inﬂ uenzae type b]), Nepal has decided 
to give the second dose of pneumococcal conjugate 
vaccine at 10 weeks, despite it being potentially less 
eﬀ ective than at 14 weeks.
Third, currently in south Asia about 8 million children 
have not had a third dose of diphtheria, tetanus, and 
pertussis vaccine in their ﬁ rst year of life9—these are 
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often the most deprived and hardest to reach groups. In 
Nepal, reaching children in remote mountainous areas 
poses particular challenges.  Addition of new vaccines, 
without improving and expanding the supply chain, 
risks stretching public health systems to the limit.
Finally, in Nepal the success of polio eradication 
has resulted in public support for immunisation; 
communities play their part to ensure every child 
is vaccinated. For governments like Nepal’s, IPV 
introduction might be mainly about the start of ﬁ nal 
polio eradication by working towards removing live 
attenuated polio vaccines. But the public might already 
regard polio as eradicated and not understand the need 
for IPV.
The Maldives is planing to be the next country in 
south Asia to introduce IPV. After that, the rest of the 
region is due to follow, including Bangladesh, Pakistan, 
Afghanistan, and India. All have signiﬁ cant public health 
challenges. It is crucial that countries share lessons 
learned as IPV is rolled out, including how to address its 
challenges.
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